VG801

DRUG2 trials

Sponsors

VeonGen Therapeutics GmbH

Conditions

Biallelic ABCA4 Mutation-Associated Retinal Dystrophy.Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1

Phase 1

Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)

RecruitingNCT07002398

VeonGen Therapeutics GmbHRetinal Dystrophy Due to Biallelic ABCA4 Mutations, Stargardt Disease 1

Start: 2024-12-23End: 2027-12-01Target: 18Updated: 2026-09-02

A Phase 1/2 Open-label, Multi-centre, Dose-exploration Trial to Evaluate the Safety and Preliminary Efficacy of VG801 via Subretinal Injection in Treatment of Patients with Biallelic ABCA4 Mutation-Associated Retinal Dystrophy.

Not yet recruitingCTIS2024-520425-37-00

VeonGen Therapeutics GmbHBiallelic ABCA4 Mutation-Associated Retinal Dystrophy.

Target: 6Updated: 2025-12-26